Intralesional Hyaluronic Acid and Verapamil Injection in Peyronie's Disease
Peyronie's Disease, Hyaluronic Acid, Verapamil
About this trial
This is an interventional treatment trial for Peyronie's Disease
Eligibility Criteria
Inclusion Criteria: Patient's age from >18 - 70 years old. A palpable nodule or plaque in the tunica of the penis Presence of pain in the flaccid state or during painful erections. Progressive penile curvature >15° and/or penile pain in the flaccid state or at the erection in the last 12 months Exclusion Criteria: Patient refusal. Calcified plaques or hourglass deformity as defined at duplex Doppler ultrasonography, Previous Peyronie's Disease therapy with oral agents or intralesional injections Severe concomitant erectile dysfunction (International Index of Erectile Function [IIEF-5] score < 7). Congenital penile curvature, history of previous penile surgery, a concomitant oral treatment for Peyronie's Disease.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Intralesional treatment with Hyaluronic acid
Intralesional treatment with Verapamil
Patients will receive intralesional treatment with Hyaluronic acid (0.8% highly purified sodium salt Hyaluronic acid 6 mg/2 mL; Sinovial, IBSA, Lodi, Italy) weekly for 12 weeks.
Patients will receive intralesional treatment with Verapamil (10 mg in 5 mL of normal saline water) weekly for 12 weeks.